Jon Congleton serves as a Director of Accoy Pharmaceuticals’ Strategy Advisory Board. He is the President and CEO of Impel NeuroPharma. Prior to Impel, he was President and Chief Executive Officer and Board member of Nivalis. Mr. Congleton was at Teva Pharmaceuticals from November 1996 to December 2014, where he served as Senior Vice President, Global Central Nervous Disorders and Pain from April 2013 to December 2014, and as Senior Vice President Global Medicine Group from November 2011 to April 2013. Prior to that, Mr. Congleton, who began his career in pharmaceutical sales, has held positions in general management and global strategic marketing, including General Manager of Teva Neuroscience. At Teva Neuroscience he was responsible for the commercialization of Copaxone® and Azilect®, both products which were market leaders and which exceeded all sales and profit forecasts for each of the four years he was responsible for the business. Mr. Congleton is conversant in all aspects of running and growing a pharmaceutical business as well as financial community relations. He earned a B.S. in marketing from Kansas State University.
Director, Strategy Advisory Board